Page last updated: 2024-10-25

ci 994 and Disease Exacerbation

ci 994 has been researched along with Disease Exacerbation in 1 studies

tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells
tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Lin, HY1
Wu, HJ1
Chen, SY1
Hou, MF1
Lin, CS1
Chu, PY1

Other Studies

1 other study available for ci 994 and Disease Exacerbation

ArticleYear
Epigenetic therapy combination of UNC0638 and CI-994 suppresses breast cancer via epigenetic remodeling of BIRC5 and GADD45A.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 145

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Cell Cycle Pr

2022